High serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.

Por Zeimet, A. G., Widschwendter, M., Uhl-Steidl, M., Müller-Holzner, E., Daxenbichler, G., Marth, C., Dapunt, O.
Publicado em 1997

Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.

Por Marth, C., Widschwendter, M., Kaern, J., Jørgensen, N. P., Windbichler, G., Zeimet, A. G., Tropé, C., Daxenbichler, G.
Publicado em 1997

Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro

Por Widschwendter, M, Widschwendter, A, Welte, T, Daxenbichler, G, Zeimet, A G, Bergant, A, Berger, J, Peyrat, J-P, Michel, S, Doppler, W, Marth, C
Publicado em 1999

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

Por Hofstetter, G, Berger, A, Schuster, E, Wolf, A, Hager, G, Vergote, I, Cadron, I, Sehouli, J, Braicu, E I, Mahner, S, Speiser, P, Marth, C, Zeimet, A G, Ulmer, H, Zeillinger, R, Concin, N
Publicado em 2011

Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference

Por Hubalek, M., Bartsch, R., Gnant, M., Kapp, K. S., Lang, A., Lax, S., Lukas, P., Neunteufel, W., Pristauz, G., Reitsamer, R., Sandbichler, P., Schrenk, P., Singer, C., Tamussino, K., Tschmelitsch, J., Zeimet, A. G., Marth, C.
Publicado em 2012